Families affected by rare diseases criticize the FDA for changing and conflicting decisions. Rare disease advocates express displeasure with mixed signals from the regulatory body. These families face challenges due to instability in approval processes. The FDA is sending mixed signals that complicate access to treatment. The article highlights the tension between patients and authorities in the field of rare diseases.